TB-500: research overview

The short version

TB-500 is a small synthetic peptide — just seven amino acids — with the sequence Ac-LKKTETQ. That sequence is the actin-binding region of a much larger natural protein called thymosin beta-4 (Tβ4). Actin is part of the internal skeleton cells use to hold their shape and move toward a wound, so the parent protein is closely associated with cell migration, tissue repair, and new blood-vessel growth ^[5].

The single most important thing to understand about TB-500 is what might be called an identity gap. In commerce and in anti-doping science, "TB-500" means the short seven-amino-acid heptapeptide (~889 Da). But most published effectiveness research was conducted with full-length thymosin beta-4, which is a 43-amino-acid protein roughly five times larger (~4,963 Da) ^[1]. It is not established that the small fragment reproduces what the full protein does. TB-500 is not an approved medicine in any jurisdiction, it is banned in competitive sport by WADA, and this page reports doses only as they were studied — never as advice.

What it is

TB-500 is a synthetic, N-terminally acetylated heptapeptide — a seven-amino-acid peptide with a small acetyl group capping its N-terminus — with the sequence Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH. This LKKTETQ stretch corresponds to residues 17–23 of thymosin beta-4 (Tβ4), a 43-amino-acid protein encoded by the gene TMSB4X, and it is the conserved actin-binding region of the beta-thymosin family.

The distinction carries real weight. The fragment sold and detected as "TB-500" weighs approximately 889 daltons; full-length Tβ4 weighs approximately 4,963 daltons. Wherever a study below used the full protein rather than the 7-mer, this page flags it, because TB-500 marketing and community discussion routinely borrow a larger molecule's data without acknowledging the gap ^[1].

How it works

Full-length thymosin beta-4 is the body's major intracellular G-actin sequestering peptide. G-actin is the free, single-unit form of actin; sequestering means Tβ4 grabs and holds those units so they are not assembled into filaments until needed. A 2-angstrom X-ray crystal structure of a gelsolin-domain-1–Tβ4 hybrid bound to actin established that Tβ4 forms a 1:1 complex with G-actin and caps both ends of the monomer, preventing polymerization — the structural basis for its actin-buffering role and its WH2 motif-dependent mechanism ^[6].

Why does actin regulation matter for repair? By controlling the actin pool, Tβ4 (and the LKKTETQ motif it contains) is associated with faster cell migration into a wound, promotion of angiogenesis (new vessel growth), anti-inflammatory and anti-cell-death signaling, reduced scar-forming myofibroblast activity, and recruitment of progenitor cells — a consolidated mechanism reviewed across dermal-wound, corneal, cardiac, and CNS injury models ^[5]. Whether the isolated seven-amino-acid fragment reproduces all of these effects at doses used in research is not established in controlled human trials ^[1].

What the research shows

Structural and mechanistic basis. The crystallography work pinned down the 1:1 G-actin capping mechanism ^[6], and a multi-model review consolidated Tβ4's actin-binding, pro-migratory, anti-scarring, anti-inflammatory, and angiogenic activities as the rationale for pursuing clinical development in wounds, cornea, and heart repair ^[5].

Human safety (full-length protein — not the TB-500 fragment). In a randomized, placebo-controlled Phase 1 study, synthetic thymosin beta-4 was administered intravenously to 40 healthy volunteers — single dose then daily for 14 days at 42, 140, 420, or 1,260 mg. The compound was well tolerated, with only infrequent mild-to-moderate adverse events, no dose-limiting toxicities, no serious adverse events, and dose-proportional pharmacokinetics ^[12]. These data are for full-length Tβ4 administered IV to healthy volunteers — not for the TB-500 heptapeptide fragment and not for subcutaneous or intramuscular injection as practiced in research-use communities.

Animal dose-response (full-length protein). In male Wistar rats with embolic middle cerebral artery occlusion, intraperitoneal thymosin beta-4 at 2 and 12 mg/kg (starting 24 hours post-stroke, then every 3 days for 4 more doses) improved neurological function from day 14 through day 56 (p<0.05); 18 mg/kg gave no significant benefit, and modeling proposed an optimal dose of approximately 3.75 mg/kg ^[11]. The non-monotonic result — more was not better — is a caution against simple loading rationales.

Field-level review. A 2026 Sports Medicine narrative review listing TB-500/thymosin beta-4 and BPC-157 among unapproved peptides for musculoskeletal injury and athletic performance concluded that many such peptides show favorable animal-model results but that rigorous human safety data are scarce, potential for serious harm exists, and these compounds operate largely outside regulatory oversight ^[1].

Reported effects, cautions & safety

The following are anecdotal, not clinical evidence — community reports from peptide-user forums, athletic and biohacker blogs, and research-supplier review pages, not controlled trial observations.

Commonly reported benefits:

• Faster recovery from tendon, ligament, and muscle injuries — very commonly reported as the primary reason people reach for TB-500; descriptions vary from days to several weeks.
• Less joint pain and stiffness, better range of motion — frequently reported; easier movement described over several weeks.
• Improved overall flexibility and mobility — frequently reported, often emerging around weeks three to four.
• Reduced inflammation or calmed-down soreness — occasionally reported as a vaguer systemic impression.
• Better wound and skin healing — occasionally reported; lines up with parent-protein animal wound data.
• Hair regrowth or thicker hair — rarely reported and inconsistent; hard to separate from other concurrent practices.

Commonly reported adverse effects:

• Injection-site redness, swelling, or aching — very commonly reported; described as mild and typically resolving within a day or two.
• Temporary tiredness or lethargy — frequently reported, especially after early doses; most users describe it fading over the first week.
• Head rush, lightheadedness, or headache — occasionally reported shortly after injecting, particularly with larger early doses.
• Brief flu-like feeling — occasionally reported in the first day or two; described as mild and short-lived.
• Nausea — rarely reported, described more with larger amounts.
• Heightened awareness of an existing injury — rarely reported in the first week or two; interpreted by users as the area "being worked on."
• Temporary low mood or mood changes — rarely reported; vague and uncommon.

Safety cautions from the literature:

• Human safety of the fragment is essentially unstudied. No completed controlled human trial exists for the TB-500 heptapeptide. A 2026 review of unapproved peptides flags scarce human safety data and potential for serious harm ^[1].
• Identity gap: fragment versus full protein. Reported benefits extrapolate from full-length Tβ4 data; applying those findings to the short TB-500 fragment is an unconfirmed extrapolation ^[1][5].
• Theoretical cancer / tumor-growth concern. Thymosin beta-4 is overexpressed in several cancers and linked to metastasis and tumor angiogenesis; the same pro-migratory, pro-angiogenic properties that may help repair could theoretically support tumor progression ^[5].
• Banned in sport. TB-500 is WADA-prohibited under peptide and growth-factor categories; anti-doping laboratories have developed detection methods for it. Competitive and tested athletes face sanctions ^[1].
• Non-monotonic animal dosing. The rat stroke study's finding that the highest dose (18 mg/kg) provided no benefit undermines simple loading rationales ^[11].
• Research-grade product quality is not guaranteed. Material sold as TB-500 for research is not manufactured to medicine-grade standards; identity, purity, and exact sequence can vary between suppliers.
• Theoretical caution in pregnancy, breastfeeding, and development. TB-500 acts on fundamental processes — cell movement and vessel growth — that are central to development. No human data exist in these populations.

Where it fits in recovery research

TB-500 occupies a specific niche on this desk: a compound whose mechanism — actin regulation driving cell migration and new vessel growth — is well described at the protein level, but whose evidence as the actual fragment sold is notably thin ^[1]. In the context of the Wolverine blend, TB-500 is the cell-migration half — the part that, through actin dynamics, is theorized to help cells reorganize and move into damaged tissue in ways that complement BPC-157's angiogenic action ^[5][6]. That makes it the clearest illustration of why this field rewards careful reading: a coherent mechanism, promising parent-protein data, and a marketed fragment that has not been independently confirmed to match. Compare both components on the comparison page.